Brought to you by 
AstraZeneca licenses ISIS-STAT3 and other antisense projects from Isis; deal expanded to include new therapy areas
19 Oct 2021
Executive Summary
One day after announcing a tie-up with long-time partner Biogen Idec, Isis Pharmaceuticals Inc. signed a deal with AstraZeneca PLC for the development of antisense therapeutics against five cancer targets.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca licenses ISIS-STAT3 and other antisense projects from Isis; deal expanded to include new therapy areas
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice